Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma

Hypofractionated Imrt (Vmat-Ra) With Temozolomide For Elderly Patients, Unsuitable For Surgery With Newly Diagnosed High Grade Glioma

To assess the effect of IMRT using VMAT rapidarc approach, followed by adjuvant temozolomide on survival and quality of life in elderly, poor performance status patients with newly diagnosed HGG.

Investigators designed this study with the aim to assess the effect of IMRT using VMAT rapidarc approach, followed by adjuvant temozolomide on survival and quality of life in elderly, poor performance status patients with newly diagnosed HGG. The potential advantage of this approach is deliver a more selective irradiation to tumor's target with reducing the dose to normal brain and to allow the delivery of a higher dose, optimizing the therapeutic window.

Inclusion Criteria:

• Patients aged ≥ 70 years

• Karnosky performance status (KPS) ≤60

• Histologically confirmed HGG after tumor biopsy

  • GBM
  • Anaplastic Astrocytoma
  • Anaplastic Oligoastrocytoma
  • Anaplastic Oligodendroglioma without IDH1 mutation and no codeletion 1p19q

• Estimated survival ≥ 3 months.

• Normal liver, Kidney and bone marrow function

• Written informed consent

Exclusion criteria:

• Prior radiation therapy
• Other primary cancer

Exclusion Criteria:

-